caa a22 4500 465789498 CHVBK 20180323112019.0 cr unu---uuuuu 170327e19900201xx s 000 0 eng 10.1007/BF00216930 doi (NATIONALLICENCE)springer-10.1007/BF00216930 An evaluation of combination 5-fluorouracil and spirogermanium in the treatment of advanced colorectal carcinoma [Elektronische Daten] [Mary McMaster, F. Anthony Greco, David Johnson, John Hainsworth] Summary: Seventeen patients with advanced colorectal carcinoma were treated with a combination of 5-fluorouracil and spirogermanium, a recently developed azaspiran-germanium compound remarkable for its lack of hematologic, gastrointestinal, renal or hepatic toxicity. Response to treatment and the incidence and severity of toxicity were evaluated. No patient achieved a complete response; there were three partial responses. Toxicity was unexpectedly frequent and severe; one patient was removed from study early due to intractable diarrhea, and there were two toxic deaths, both attributable to neutropenia and sepsis. Significant toxicity occurred in all seventeen patients, including three instances of Grade 3 or 4 hematologic toxicity. Given the low response rate and high incidence of life-threatening toxicity, we do not recommend further evaluation of this schedule of 5-fluorouracil and spirogermanium in the treatment of colorectal carcinoma. Kluwer Academic Publishers, 1990 colorectal cancer nationallicence 5-fluorouracil nationallicence spirogermanium nationallicence McMaster Mary Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA aut Anthony Greco F. Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA aut Johnson David Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA aut Hainsworth John Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA aut Investigational New Drugs Kluwer Academic Publishers 8/1(1990-02-01), 87-92 0167-6997 8:1<87 1990 8 10637 https://doi.org/10.1007/BF00216930 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00216930 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- McMaster Mary Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA aut NATIONALLICENCE 700 1- Anthony Greco F. Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA aut NATIONALLICENCE 700 1- Johnson David Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA aut NATIONALLICENCE 700 1- Hainsworth John Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/1(1990-02-01), 87-92 0167-6997 8:1<87 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer